Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 343 participants.

Also called NCT01898221

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 343 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01898221
Other papers using this trial's data
  • Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial JAMA, 2020-10-27 DOI, PubMed 33107945, PMC7592031 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01898221. Randomized; single masking; primary purpose treatment. Start 2013-10 (actual); primary completion 2019-12 (actual). Results posted on 2025-08-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Acronym
VOM-R01
Condition
Ventricular Tachycardia
Intervention (Drug)
Ethanol
Intervention (Procedure)
Ablation
Lead sponsor
The Methodist Hospital Research Institute (class: other)
Collaborator
National Institutes of Health (NIH) (class: US National Institutes of Health)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct01898221
Content hash
c6ce1d7c4d0067ea36455d23b9474ff72a0318955169d6ab1fc4c4ac0d87a9a3